Výsledky vyhledávání

Akademický článek

Discovery and insights from DSX mission’s high-power VLF wave transmission experiments in the radiation belts

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)

Abstract Space weather phenomena can threaten space technologies. A hazard among these is the population of relativistic electrons in the Van Allen radiation belts. To reduce the threat, artificial processes can be introduced by transmitting very-low

Externí odkaz: https://doaj.org/article/f72f17a7534841798364af3e7695988c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Space-to-space very low frequency radio transmission in the magnetosphere using the DSX and Arase satellites

Publikováno v: Earth, Planets and Space, Vol 74, Iss 1, Pp 1-9 (2022)

Abstract Very low frequency (VLF) waves (about 3–30 kHz) in the Earth’s magnetosphere interact strongly with energetic electrons and are a key element in controlling dynamics of the Van Allen radiation belts. Bistatic very low frequency (VLF) tra

Externí odkaz: https://doaj.org/article/2c52696ab0e2449996ae30a37c40f695

Zobrazit plný text záznamu

P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease

Autor: J F Colombel, P Irving, F Rieder, R Panaccione, D Schwartz, R Hayashi, X Zhu, A P Lacerda, E Dubcenco, E Marced, P Hecht, T Feng, S Berg, W Reinisch

Publikováno v: Journal of Crohn's and Colitis. 17:i620-i623

Background Intestinal and perianal fistulas and fissures are associated with significant morbidity and decreased quality of life in patients with Crohn’s disease (CD). We evaluated rates of fistula and fissure improvements with upadacitinib (UPA),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e96971948055d7bdf36d704264d886
https://doi.org/10.1093/ecco-jcc/jjac190.0621

Zobrazit plný text záznamu

P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD

Publikováno v: Journal of Crohn's and Colitis. 17:i794-i797

Background Recruitment rates for phase 2b/3 randomized controlled trials (RCTs) in IBD have substantially dropped over time. Several steps are required prior to successful patient randomization. Initially the physician must propose a trial to a poten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c64c0b4a6137305b48722054b0293fb2
https://doi.org/10.1093/ecco-jcc/jjac190.0794

Zobrazit plný text záznamu

A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY

Autor: C Pray, N Narula, E C Wong, J K Marshall, S Rangarajan, S Islam, A Bahonar, K F Alhabib, A Kontsevaya, F Ariffin, H U Co, W Al Sharief, A Szuba, A Wielgosz, M L Diaz, R Yusuf, L Kruger, B Soman, Y Li, C Wang, L Yin, M Erkin, F Lanas, K Davletov, A Rosengren, P Lopez-Jaramillo, R Khatib, A Oguz, R Iqbal, K Yeates, Á Avezum, W Reinisch, P Moayyedi, S Yusuf

Publikováno v: Journal of the Canadian Association of Gastroenterology. 6:20-22

Background The pathogenesis of inflammatory bowel disease (IBD) which includes Crohn’s disease (CD) and ulcerative colitis (UC), is believed to involve activation of the intestinal immune system in response to the gut microbiome among genetically s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::efe1790be6bd051f34ff049f00e38877
https://doi.org/10.1093/jcag/gwac036.176

Zobrazit plný text záznamu

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

Autor: L Peyrin-Biroulet, P Bossuyt, D Bettenworth, E V Loftus Jr., S Anjie, G D’Haens, M Saruta, P Arkkila, D H Kim, D Choi, W Reinisch

Publikováno v: Journal of Crohn's and Colitis. 17:i574-i576

Background Network meta-analysis (NMA) using randomised controlled trial (RCT) data can provide indirect evidence on comparative efficacy of various treatments.1 The NMA reported herein was conducted to evaluate infliximab (IFX) and vedolizumab (VDZ)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30bea3ce999b872696b6241a8ff55d60
https://doi.org/10.1093/ecco-jcc/jjac190.0575

Zobrazit plný text záznamu

P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study

Autor: S Schreiber, W Reinisch, D Nguyen, T Guerin, J Kierkus, P Rozpondek, D Bourdet, B Abhyankar, L Peyrin-Biroulet

Publikováno v: Journal of Crohn's and Colitis. 17:i505-i507

Background The unmet need in Crohn’s disease (CD) exists for new medications with an optimized risk-benefit ratio with avoidance of systemic side effects. This Phase 2 study evaluated the efficacy and safety of the oral, once-daily, gut-selective p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::96931872b93518512f3b9010ec9178de
https://doi.org/10.1093/ecco-jcc/jjac190.0505

Zobrazit plný text záznamu

P752 Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis

Autor: S Vermeire, B Abraham, B Bressler, W Reinisch, J E Axelrad, A Jain, A Memaj, L Akukwe, W J Liu, M T Osterman, J B Canavan, B E Sands

Publikováno v: Journal of Crohn's and Colitis. 17:i882-i884

Background Ozanimod (OZA) is approved in the EU, US, and other countries for the treatment of moderately to severely active ulcerative colitis (UC) in adults based on the phase 3 True North (TN) trial. Data on time to disease relapse in patients (pts

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3cd31fb2ecfe762abde31b949f7b342
https://doi.org/10.1093/ecco-jcc/jjac190.0882

Zobrazit plný text záznamu

P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

Autor: L Peyrin-Biroulet, M C Dubinsky, B E Sands, J Panés, S Schreiber, W Reinisch, B G Feagan, S Danese, A Yarur, G D’Haens, M Goetsch, K Wosik, J Wu, I Modesto, A McDonnell, L Bartolome, C J Rabbat, S Vermeire

Publikováno v: Journal of Crohn's and Colitis. 17:i536-i538

Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). Although ≈30% of UC patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ea1c9b1e704bac22ab40c069cda1fc6
https://doi.org/10.1093/ecco-jcc/jjac190.0537

Zobrazit plný text záznamu

P462 Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders

Autor: E Wong, P Dulai, J Marshall, V Jairath, W Reinisch, N Narula

Publikováno v: Journal of Crohn's and Colitis. 17:i589-i591

Background Differences in one-year outcomes among early compared to delayed responders to vedolizumab have been demonstrated in ulcerative colitis. However, it is unclear whether differences exist with ustekinumab, and what factors differentiate dela

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d450d2520a4507665638aeef63a207a
https://doi.org/10.1093/ecco-jcc/jjac190.0592

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání